News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
496,465 Results
Type
Article (29101)
Company Profile (97)
Press Release (467267)
Section
Business (148931)
Career Advice (836)
Deals (25633)
Drug Delivery (49)
Drug Development (56365)
Employer Resources (71)
FDA (13327)
Job Trends (10809)
News (249699)
Policy (23339)
Tag
Academia (1872)
Alliances (34319)
Alzheimer's disease (833)
Approvals (13296)
Artificial intelligence (101)
Bankruptcy (206)
Best Places to Work (8531)
Biotechnology (71)
Breast cancer (97)
Cancer (799)
Cardiovascular disease (75)
Career advice (737)
Cell therapy (147)
Clinical research (46122)
Collaboration (262)
Compensation (100)
COVID-19 (1616)
C-suite (78)
Data (880)
Diabetes (112)
Diagnostics (4493)
Earnings (59422)
Employer resources (69)
Events (74557)
Executive appointments (258)
FDA (13787)
Funding (248)
Gene therapy (91)
GLP-1 (381)
Government (3169)
Healthcare (14709)
Infectious disease (1663)
Inflammatory bowel disease (75)
Interviews (89)
IPO (11732)
Job creations (2564)
Job search strategy (674)
Layoffs (220)
Legal (5137)
Lung cancer (131)
Manufacturing (86)
Medical device (13115)
Medtech (13120)
Mergers & acquisitions (13984)
Metabolic disorders (287)
Neuroscience (1023)
NextGen Class of 2024 (4776)
Non-profit (3239)
Northern California (1041)
Obesity (163)
Opinion (85)
People (45775)
Phase I (13537)
Phase II (20168)
Phase III (16004)
Pipeline (372)
Postmarket research (1904)
Preclinical (4809)
Press Release (69)
Radiopharmaceuticals (192)
Rare diseases (122)
Real estate (3984)
Regulatory (16009)
Research institute (1744)
Resumes & cover letters (106)
Southern California (900)
Startups (2585)
United States (9769)
Vaccines (307)
Weight loss (119)
Date
Today (59)
Last 7 days (482)
Last 30 days (2687)
Last 365 days (26223)
2024 (24066)
2023 (29951)
2022 (39538)
2021 (42698)
2020 (41190)
2019 (35079)
2018 (26763)
2017 (24153)
2016 (23172)
2015 (27832)
2014 (21486)
2013 (17902)
2012 (19262)
2011 (19780)
2010 (18595)
Location
Africa (477)
Arizona (112)
Asia (29099)
Australia (4511)
California (2269)
Canada (1068)
China (186)
Colorado (103)
Connecticut (111)
Europe (59829)
Florida (353)
Georgia (83)
Illinois (262)
Indiana (156)
Kansas (75)
Maryland (469)
Massachusetts (1722)
Michigan (121)
Minnesota (239)
New Jersey (780)
New York (713)
North Carolina (554)
Northern California (1041)
Ohio (100)
Pennsylvania (628)
South America (724)
Southern California (900)
Texas (351)
Utah (70)
Washington State (190)
496,465 Results for "profound medical corp".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Profound Medical Announces Third Quarter 2024 Financial Results
November 8, 2024
·
15 min read
Business
Profound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow
Profound Medical Corp. will announce its first quarter 2024 financial results after market close on Thursday, May 9, 2024.
April 22, 2024
·
2 min read
Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
Profound Medical Corp. today announced that management will present an update on the Company’s business at the 2024 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 16, 2024 at 9:30 a.m. Eastern Time at the Metro Toronto Convention.
April 9, 2024
·
2 min read
Press Releases
Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer
October 17, 2024
·
7 min read
Business
Profound Medical Announces Fourth Quarter and Full Year 2023 Financial Results
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the fourth quarter and full year ended December 31, 2023.
March 7, 2024
·
13 min read
Profound Medical in Collaboration with Siemens Healthineers to Further Expand Physician and Patient Access to the TULSA Procedure
Profound Medical Corp. announced that it has entered into a non-exclusive collaboration with Siemens Healthineers, a global leader in medical technology.
February 27, 2024
·
7 min read
Profound Medical to Participate in Barclays 26th Annual Global Healthcare Conference
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today announced that management will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference on Wednesday, March 13, 2024 at 11:15 a.m. Eastern Time at the Loews Miami Beach Hotel.
March 4, 2024
·
2 min read
Growing Body of Clinical Evidence Points to the Potential of Profound Medical’s TULSA Procedure Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum
Profound Medical Corp. is pleased to announce that a total of 25 paper, poster and podium presentations highlighting the Transurethral Ultrasound Ablation procedure’s ability to effectively, safely and efficiently treat an unrivaled variety of prostate cancer and/or benign prostatic hyperplasia patients have been made at major medical meetings already in 2024.
May 6, 2024
·
6 min read
FDA
Profound Medical Receives U.S. FDA 510(k) Clearance for ‘Contouring Assistant’ AI Module that Enables Creation of an Automated TULSA Treatment Plan
Profound Medical Corp. today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for the Company’s second TULSA-AI module, Contouring Assistant, for use in conjunction with its TULSA-PRO® system.
May 14, 2024
·
8 min read
Business
Profound Medical to Release Fourth Quarter and Full Year 2023 Financial Results on March 7 – Conference Call to Follow
Profound Medical Corp. will announce its fourth quarter and full year 2023 financial results after market close on Thursday, March 7, 2024.
February 15, 2024
·
2 min read
1 of 49,647
Next